APO Research
Talk to an analyst

APO RESEARCH · REPORT

Direct Thrombin Inhibitors (DTIs)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Direct Thrombin Inhibitors (DTIs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025196 pages

Choose your research edition.

Industry ResearchDirect Thrombin Inhibitors (DTIs) Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Direct Thrombin Inhibitors (DTIs) Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Direct Thrombin Inhibitors (DTIs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Direct Thrombin Inhibitors (DTIs) Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Direct Thrombin Inhibitors (DTIs) Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Direct Thrombin Inhibitors (DTIs) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Direct Thrombin Inhibitors (DTIs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Direct Thrombin Inhibitors (DTIs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Direct Thrombin Inhibitors (DTIs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Direct Thrombin Inhibitors (DTIs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Direct Thrombin Inhibitors (DTIs) include Accord Healthcare, Amneal Pharms, Apotex, Boehringer Ingelheim, Dr.Reddy's Laboratories, Eugia Pharma, Fresenius Kabi, GlaxoSmithKline and Hikma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Direct Thrombin Inhibitors (DTIs) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Direct Thrombin Inhibitors (DTIs) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Direct Thrombin Inhibitors (DTIs) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Direct Thrombin Inhibitors (DTIs) market size, projected growth trends, production technologies, key applications, and end-use industries.

Direct Thrombin Inhibitors (DTIs) Segment by Company

Accord Healthcare

Amneal Pharms

Apotex

Boehringer Ingelheim

Dr.Reddy's Laboratories

Eugia Pharma

Fresenius Kabi

GlaxoSmithKline

Hikma

Mitsubishi Tanabe Pharma

MSN

Pfizer

Sandoz

Teva Pharmaceutical

The Medicines Company

Beijing Baiao Pharmaceutical

BrightGene

Chengdu Brilliant Pharmaceutical

Hainan Poly Pharm

Hainan Shuangcheng Pharmaceuticals

Hansoh Pharma

Lunan Pharmaceutical

Qilu Pharmaceutical

CSPC Ouyi Pharmaceutical

Yangtze River Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Direct Thrombin Inhibitors (DTIs) Segment by Type

Oral DTIs

Parenteral DTIs

Direct Thrombin Inhibitors (DTIs) Segment by Application

Pulmonary Embolism

Deep Vein Thrombosis

Atrial Fibrillation

Thrombocytopenia

Other

Direct Thrombin Inhibitors (DTIs) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Direct Thrombin Inhibitors (DTIs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Direct Thrombin Inhibitors (DTIs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Direct Thrombin Inhibitors (DTIs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Direct Thrombin Inhibitors (DTIs) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Direct Thrombin Inhibitors (DTIs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Direct Thrombin Inhibitors (DTIs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Direct Thrombin Inhibitors (DTIs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Direct Thrombin Inhibitors (DTIs) Industry Trends Table 2. Direct Thrombin Inhibitors (DTIs) Industry Drivers Table 3. Direct Thrombin Inhibitors (DTIs) Industry Opportunities and Challenges Table 4. Direct Thrombin Inhibitors (DTIs) Industry Restraints Table 5. Global Direct Thrombin Inhibitors (DTIs) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Direct Thrombin Inhibitors (DTIs) Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Direct Thrombin Inhibitors (DTIs) Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Direct Thrombin Inhibitors (DTIs) Sales Market Share by Manufacturers Table 9. Global Direct Thrombin Inhibitors (DTIs) Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Direct Thrombin Inhibitors (DTIs) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Direct Thrombin Inhibitors (DTIs) Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Direct Thrombin Inhibitors (DTIs) Manufacturers, Product Type & Application Table 13. Global Direct Thrombin Inhibitors (DTIs) Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Direct Thrombin Inhibitors (DTIs) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Oral DTIs Table 17. Major Manufacturers of Parenteral DTIs Table 18. Global Direct Thrombin Inhibitors (DTIs) Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Direct Thrombin Inhibitors (DTIs) Sales by Type (2021-2026) & (K Units) Table 20. Global Direct Thrombin Inhibitors (DTIs) Sales by Type (2027-2032) & (K Units) Table 21. Global Direct Thrombin Inhibitors (DTIs) Sales Market Share by Type (2021-2026) Table 22. Global Direct Thrombin Inhibitors (DTIs) Sales Market Share by Type (2027-2032) Table 23. Global Direct Thrombin Inhibitors (DTIs) Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Direct Thrombin Inhibitors (DTIs) Revenue by Type (2021-2026) & (K Units) Table 25. Global Direct Thrombin Inhibitors (DTIs) Revenue by Type (2027-2032) & (K Units) Table 26. Global Direct Thrombin Inhibitors (DTIs) Revenue Market Share by Type (2021-2026) Table 27. Global Direct Thrombin Inhibitors (DTIs) Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Pulmonary Embolism Table 29. Major Manufacturers of Deep Vein Thrombosis Table 30. Major Manufacturers of Atrial Fibrillation Table 31. Major Manufacturers of Thrombocytopenia Table 32. Major Manufacturers of Other Table 33. Global Direct Thrombin Inhibitors (DTIs) Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Direct Thrombin Inhibitors (DTIs) Sales by Application (2021-2026) & (K Units) Table 35. Global Direct Thrombin Inhibitors (DTIs) Sales by Application (2027-2032) & (K Units) Table 36. Global Direct Thrombin Inhibitors (DTIs) Sales Market Share by Application (2021-2026) Table 37. Global Direct Thrombin Inhibitors (DTIs) Sales Market Share by Application (2027-2032) Table 38. Global Direct Thrombin Inhibitors (DTIs) Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Direct Thrombin Inhibitors (DTIs) Revenue by Application (2021-2026) & (K Units) Table 40. Global Direct Thrombin Inhibitors (DTIs) Revenue by Application (2027-2032) & (K Units) Table 41. Global Direct Thrombin Inhibitors (DTIs) Revenue Market Share by Application (2021-2026) Table 42. Global Direct Thrombin Inhibitors (DTIs) Revenue Market Share by Application (2027-2032) Table 43. Global Direct Thrombin Inhibitors (DTIs) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Direct Thrombin Inhibitors (DTIs) Sales by Region (2021-2026) & (K Units) Table 45. Global Direct Thrombin Inhibitors (DTIs) Sales Market Share by Region (2021-2026) Table 46. Global Direct Thrombin Inhibitors (DTIs) Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Direct Thrombin Inhibitors (DTIs) Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Direct Thrombin Inhibitors (DTIs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Direct Thrombin Inhibitors (DTIs) Sales by Country (2021-2026) & (K Units) Table 50. North America Direct Thrombin Inhibitors (DTIs) Sales by Country (2027-2032) & (K Units) Table 51. Europe Direct Thrombin Inhibitors (DTIs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Direct Thrombin Inhibitors (DTIs) Sales by Country (2021-2026) & (K Units) Table 53. Europe Direct Thrombin Inhibitors (DTIs) Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Direct Thrombin Inhibitors (DTIs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Direct Thrombin Inhibitors (DTIs) Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Direct Thrombin Inhibitors (DTIs) Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales by Country (2027-2032) & (K Units) Table 60. Global Direct Thrombin Inhibitors (DTIs) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Direct Thrombin Inhibitors (DTIs) Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Direct Thrombin Inhibitors (DTIs) Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Direct Thrombin Inhibitors (DTIs) Revenue Market Share by Region (2021-2026) Table 64. Global Direct Thrombin Inhibitors (DTIs) Revenue Market Share by Region (2027-2032) Table 65. Accord Healthcare Company Information Table 66. Accord Healthcare Business Overview Table 67. Accord Healthcare Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Accord Healthcare Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 69. Accord Healthcare Recent Development Table 70. Amneal Pharms Company Information Table 71. Amneal Pharms Business Overview Table 72. Amneal Pharms Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Amneal Pharms Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 74. Amneal Pharms Recent Development Table 75. Apotex Company Information Table 76. Apotex Business Overview Table 77. Apotex Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Apotex Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 79. Apotex Recent Development Table 80. Boehringer Ingelheim Company Information Table 81. Boehringer Ingelheim Business Overview Table 82. Boehringer Ingelheim Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Boehringer Ingelheim Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 84. Boehringer Ingelheim Recent Development Table 85. Dr.Reddy's Laboratories Company Information Table 86. Dr.Reddy's Laboratories Business Overview Table 87. Dr.Reddy's Laboratories Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Dr.Reddy's Laboratories Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 89. Dr.Reddy's Laboratories Recent Development Table 90. Eugia Pharma Company Information Table 91. Eugia Pharma Business Overview Table 92. Eugia Pharma Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Eugia Pharma Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 94. Eugia Pharma Recent Development Table 95. Fresenius Kabi Company Information Table 96. Fresenius Kabi Business Overview Table 97. Fresenius Kabi Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Fresenius Kabi Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 99. Fresenius Kabi Recent Development Table 100. GlaxoSmithKline Company Information Table 101. GlaxoSmithKline Business Overview Table 102. GlaxoSmithKline Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. GlaxoSmithKline Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 104. GlaxoSmithKline Recent Development Table 105. Hikma Company Information Table 106. Hikma Business Overview Table 107. Hikma Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Hikma Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 109. Hikma Recent Development Table 110. Mitsubishi Tanabe Pharma Company Information Table 111. Mitsubishi Tanabe Pharma Business Overview Table 112. Mitsubishi Tanabe Pharma Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Mitsubishi Tanabe Pharma Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 114. Mitsubishi Tanabe Pharma Recent Development Table 115. MSN Company Information Table 116. MSN Business Overview Table 117. MSN Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. MSN Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 119. MSN Recent Development Table 120. Pfizer Company Information Table 121. Pfizer Business Overview Table 122. Pfizer Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Pfizer Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 124. Pfizer Recent Development Table 125. Sandoz Company Information Table 126. Sandoz Business Overview Table 127. Sandoz Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Sandoz Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 129. Sandoz Recent Development Table 130. Teva Pharmaceutical Company Information Table 131. Teva Pharmaceutical Business Overview Table 132. Teva Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Teva Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 134. Teva Pharmaceutical Recent Development Table 135. The Medicines Company Company Information Table 136. The Medicines Company Business Overview Table 137. The Medicines Company Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. The Medicines Company Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 139. The Medicines Company Recent Development Table 140. Beijing Baiao Pharmaceutical Company Information Table 141. Beijing Baiao Pharmaceutical Business Overview Table 142. Beijing Baiao Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Beijing Baiao Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 144. Beijing Baiao Pharmaceutical Recent Development Table 145. BrightGene Company Information Table 146. BrightGene Business Overview Table 147. BrightGene Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. BrightGene Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 149. BrightGene Recent Development Table 150. Chengdu Brilliant Pharmaceutical Company Information Table 151. Chengdu Brilliant Pharmaceutical Business Overview Table 152. Chengdu Brilliant Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 153. Chengdu Brilliant Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 154. Chengdu Brilliant Pharmaceutical Recent Development Table 155. Hainan Poly Pharm Company Information Table 156. Hainan Poly Pharm Business Overview Table 157. Hainan Poly Pharm Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 158. Hainan Poly Pharm Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 159. Hainan Poly Pharm Recent Development Table 160. Hainan Shuangcheng Pharmaceuticals Company Information Table 161. Hainan Shuangcheng Pharmaceuticals Business Overview Table 162. Hainan Shuangcheng Pharmaceuticals Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 163. Hainan Shuangcheng Pharmaceuticals Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 164. Hainan Shuangcheng Pharmaceuticals Recent Development Table 165. Hansoh Pharma Company Information Table 166. Hansoh Pharma Business Overview Table 167. Hansoh Pharma Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 168. Hansoh Pharma Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 169. Hansoh Pharma Recent Development Table 170. Lunan Pharmaceutical Company Information Table 171. Lunan Pharmaceutical Business Overview Table 172. Lunan Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 173. Lunan Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 174. Lunan Pharmaceutical Recent Development Table 175. Qilu Pharmaceutical Company Information Table 176. Qilu Pharmaceutical Business Overview Table 177. Qilu Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 178. Qilu Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 179. Qilu Pharmaceutical Recent Development Table 180. CSPC Ouyi Pharmaceutical Company Information Table 181. CSPC Ouyi Pharmaceutical Business Overview Table 182. CSPC Ouyi Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 183. CSPC Ouyi Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 184. CSPC Ouyi Pharmaceutical Recent Development Table 185. Yangtze River Pharmaceutical Company Information Table 186. Yangtze River Pharmaceutical Business Overview Table 187. Yangtze River Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 188. Yangtze River Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 189. Yangtze River Pharmaceutical Recent Development Table 190. Chia Tai Tianqing Pharmaceutical Company Information Table 191. Chia Tai Tianqing Pharmaceutical Business Overview Table 192. Chia Tai Tianqing Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 193. Chia Tai Tianqing Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 194. Chia Tai Tianqing Pharmaceutical Recent Development Table 195. Key Raw Materials Table 196. Raw Materials Key Suppliers Table 197. Direct Thrombin Inhibitors (DTIs) Distributors List Table 198. Direct Thrombin Inhibitors (DTIs) Customers List Table 199. Research Programs/Design for This Report Table 200. Authors List of This Report Table 201. Secondary Sources Table 202. Primary Sources List of Figures Figure 1. Direct Thrombin Inhibitors (DTIs) Product Image Figure 2. Global Direct Thrombin Inhibitors (DTIs) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Direct Thrombin Inhibitors (DTIs) Market Size (2021-2032) & (US$ Million) Figure 4. Global Direct Thrombin Inhibitors (DTIs) Sales (2021-2032) & (K Units) Figure 5. Global Direct Thrombin Inhibitors (DTIs) Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Direct Thrombin Inhibitors (DTIs) Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Oral DTIs Image Figure 9. Parenteral DTIs Image Figure 10. Global Direct Thrombin Inhibitors (DTIs) Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Direct Thrombin Inhibitors (DTIs) Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Direct Thrombin Inhibitors (DTIs) Sales Market Share by Type (2021-2032) Figure 13. Global Direct Thrombin Inhibitors (DTIs) Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Direct Thrombin Inhibitors (DTIs) Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Direct Thrombin Inhibitors (DTIs) Revenue Market Share by Type (2021-2032) Figure 16. Pulmonary Embolism Image Figure 17. Deep Vein Thrombosis Image Figure 18. Atrial Fibrillation Image Figure 19. Thrombocytopenia Image Figure 20. Other Image Figure 21. Global Direct Thrombin Inhibitors (DTIs) Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Direct Thrombin Inhibitors (DTIs) Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Direct Thrombin Inhibitors (DTIs) Sales Market Share by Application (2021-2032) Figure 24. Global Direct Thrombin Inhibitors (DTIs) Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Direct Thrombin Inhibitors (DTIs) Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Direct Thrombin Inhibitors (DTIs) Revenue Market Share by Application (2021-2032) Figure 27. North America Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Direct Thrombin Inhibitors (DTIs) Sales Market Share by Country (2021-2032) Figure 29. U.S. Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Direct Thrombin Inhibitors (DTIs) Sales Market Share by Country (2021-2032) Figure 34. Germany Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Direct Thrombin Inhibitors (DTIs) Sales Market Share by Country (2021-2032) Figure 41. China Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales Market Share by Country (2021-2032) Figure 49. Brazil Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Direct Thrombin Inhibitors (DTIs) Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Direct Thrombin Inhibitors (DTIs) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Direct Thrombin Inhibitors (DTIs) Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Direct Thrombin Inhibitors (DTIs) Revenue (2021-2032) & (US$ Million) Figure 60. North America Direct Thrombin Inhibitors (DTIs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Direct Thrombin Inhibitors (DTIs) Revenue (2021-2032) & (US$ Million) Figure 62. Europe Direct Thrombin Inhibitors (DTIs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Direct Thrombin Inhibitors (DTIs) Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Direct Thrombin Inhibitors (DTIs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Direct Thrombin Inhibitors (DTIs) Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Direct Thrombin Inhibitors (DTIs) Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Oral DTIs
  • Parenteral DTIs
Applications
  • Pulmonary Embolism
  • Deep Vein Thrombosis
  • Atrial Fibrillation
  • Thrombocytopenia
  • Other
Companies covered
  • Accord Healthcare
  • Amneal Pharms
  • Apotex
  • Boehringer Ingelheim
  • Dr.Reddy's Laboratories
  • Eugia Pharma
  • Fresenius Kabi
  • GlaxoSmithKline
  • Hikma
  • Mitsubishi Tanabe Pharma
  • MSN
  • Pfizer
  • Sandoz
  • Teva Pharmaceutical
  • The Medicines Company
  • Beijing Baiao Pharmaceutical
  • BrightGene
  • Chengdu Brilliant Pharmaceutical
  • Hainan Poly Pharm
  • Hainan Shuangcheng Pharmaceuticals
  • Hansoh Pharma
  • Lunan Pharmaceutical
  • Qilu Pharmaceutical
  • CSPC Ouyi Pharmaceutical
  • Yangtze River Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Direct Thrombin Inhibitors (DTIs) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Direct Thrombin Inhibitors (DTIs) Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Direct Thrombin Inhibitors (DTIs) Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Direct Thrombin Inhibitors (DTIs) Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Direct Thrombin Inhibitors (DTIs) Market Dynamics
  1. 2.1 Direct Thrombin Inhibitors (DTIs) Industry Trends
  2. 2.2 Direct Thrombin Inhibitors (DTIs) Industry Drivers
  3. 2.3 Direct Thrombin Inhibitors (DTIs) Industry Opportunities and Challenges
  4. 2.4 Direct Thrombin Inhibitors (DTIs) Industry Restraints
3 Direct Thrombin Inhibitors (DTIs) Market by Manufacturers
  1. 3.1 Global Direct Thrombin Inhibitors (DTIs) Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Direct Thrombin Inhibitors (DTIs) Sales by Manufacturers (2021-2026)
  3. 3.3 Global Direct Thrombin Inhibitors (DTIs) Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Direct Thrombin Inhibitors (DTIs) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Direct Thrombin Inhibitors (DTIs) Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Direct Thrombin Inhibitors (DTIs) Manufacturers, Product Type & Application
  7. 3.7 Global Direct Thrombin Inhibitors (DTIs) Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Direct Thrombin Inhibitors (DTIs) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Direct Thrombin Inhibitors (DTIs) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Direct Thrombin Inhibitors (DTIs) Tier 1, Tier 2, and Tier 3
4 Direct Thrombin Inhibitors (DTIs) Market by Type
  1. 4.1 Direct Thrombin Inhibitors (DTIs) Type Introduction
  2. 4.1.1 Oral DTIs
  3. 4.1.2 Parenteral DTIs
  4. 4.2 Global Direct Thrombin Inhibitors (DTIs) Sales by Type
  5. 4.2.1 Global Direct Thrombin Inhibitors (DTIs) Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Direct Thrombin Inhibitors (DTIs) Sales by Type (2021-2032)
  7. 4.2.3 Global Direct Thrombin Inhibitors (DTIs) Sales Market Share by Type (2021-2032)
  8. 4.3 Global Direct Thrombin Inhibitors (DTIs) Revenue by Type
  9. 4.3.1 Global Direct Thrombin Inhibitors (DTIs) Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Direct Thrombin Inhibitors (DTIs) Revenue by Type (2021-2032)
  11. 4.3.3 Global Direct Thrombin Inhibitors (DTIs) Revenue Market Share by Type (2021-2032)
5 Direct Thrombin Inhibitors (DTIs) Market by Application
  1. 5.1 Direct Thrombin Inhibitors (DTIs) Application Introduction
  2. 5.1.1 Pulmonary Embolism
  3. 5.1.2 Deep Vein Thrombosis
  4. 5.1.3 Atrial Fibrillation
  5. 5.1.4 Thrombocytopenia
  6. 5.1.5 Other
  7. 5.2 Global Direct Thrombin Inhibitors (DTIs) Sales by Application
  8. 5.2.1 Global Direct Thrombin Inhibitors (DTIs) Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Direct Thrombin Inhibitors (DTIs) Sales by Application (2021-2032)
  10. 5.2.3 Global Direct Thrombin Inhibitors (DTIs) Sales Market Share by Application (2021-2032)
  11. 5.3 Global Direct Thrombin Inhibitors (DTIs) Revenue by Application
  12. 5.3.1 Global Direct Thrombin Inhibitors (DTIs) Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Direct Thrombin Inhibitors (DTIs) Revenue by Application (2021-2032)
  14. 5.3.3 Global Direct Thrombin Inhibitors (DTIs) Revenue Market Share by Application (2021-2032)
6 Global Direct Thrombin Inhibitors (DTIs) Sales by Region
  1. 6.1 Global Direct Thrombin Inhibitors (DTIs) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Direct Thrombin Inhibitors (DTIs) Sales by Region (2021-2032)
  3. 6.2.1 Global Direct Thrombin Inhibitors (DTIs) Sales by Region (2021-2026)
  4. 6.2.2 Global Direct Thrombin Inhibitors (DTIs) Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Direct Thrombin Inhibitors (DTIs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Direct Thrombin Inhibitors (DTIs) Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Direct Thrombin Inhibitors (DTIs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Direct Thrombin Inhibitors (DTIs) Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Direct Thrombin Inhibitors (DTIs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Direct Thrombin Inhibitors (DTIs) Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Direct Thrombin Inhibitors (DTIs) Revenue by Region
  1. 7.1 Global Direct Thrombin Inhibitors (DTIs) Revenue by Region
  2. 7.1.1 Global Direct Thrombin Inhibitors (DTIs) Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Direct Thrombin Inhibitors (DTIs) Revenue by Region (2021-2026)
  4. 7.1.3 Global Direct Thrombin Inhibitors (DTIs) Revenue by Region (2027-2032)
  5. 7.1.4 Global Direct Thrombin Inhibitors (DTIs) Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Direct Thrombin Inhibitors (DTIs) Revenue (2021-2032)
  8. 7.2.2 North America Direct Thrombin Inhibitors (DTIs) Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Direct Thrombin Inhibitors (DTIs) Revenue (2021-2032)
  11. 7.3.2 Europe Direct Thrombin Inhibitors (DTIs) Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Direct Thrombin Inhibitors (DTIs) Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Direct Thrombin Inhibitors (DTIs) Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Direct Thrombin Inhibitors (DTIs) Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Direct Thrombin Inhibitors (DTIs) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Accord Healthcare
  2. 8.1.1 Accord Healthcare Company Information
  3. 8.1.2 Accord Healthcare Business Overview
  4. 8.1.3 Accord Healthcare Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Accord Healthcare Direct Thrombin Inhibitors (DTIs) Product Portfolio
  6. 8.1.5 Accord Healthcare Recent Developments
  7. 8.2 Amneal Pharms
  8. 8.2.1 Amneal Pharms Company Information
  9. 8.2.2 Amneal Pharms Business Overview
  10. 8.2.3 Amneal Pharms Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Amneal Pharms Direct Thrombin Inhibitors (DTIs) Product Portfolio
  12. 8.2.5 Amneal Pharms Recent Developments
  13. 8.3 Apotex
  14. 8.3.1 Apotex Company Information
  15. 8.3.2 Apotex Business Overview
  16. 8.3.3 Apotex Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Apotex Direct Thrombin Inhibitors (DTIs) Product Portfolio
  18. 8.3.5 Apotex Recent Developments
  19. 8.4 Boehringer Ingelheim
  20. 8.4.1 Boehringer Ingelheim Company Information
  21. 8.4.2 Boehringer Ingelheim Business Overview
  22. 8.4.3 Boehringer Ingelheim Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Boehringer Ingelheim Direct Thrombin Inhibitors (DTIs) Product Portfolio
  24. 8.4.5 Boehringer Ingelheim Recent Developments
  25. 8.5 Dr.Reddy's Laboratories
  26. 8.5.1 Dr.Reddy's Laboratories Company Information
  27. 8.5.2 Dr.Reddy's Laboratories Business Overview
  28. 8.5.3 Dr.Reddy's Laboratories Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Dr.Reddy's Laboratories Direct Thrombin Inhibitors (DTIs) Product Portfolio
  30. 8.5.5 Dr.Reddy's Laboratories Recent Developments
  31. 8.6 Eugia Pharma
  32. 8.6.1 Eugia Pharma Company Information
  33. 8.6.2 Eugia Pharma Business Overview
  34. 8.6.3 Eugia Pharma Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Eugia Pharma Direct Thrombin Inhibitors (DTIs) Product Portfolio
  36. 8.6.5 Eugia Pharma Recent Developments
  37. 8.7 Fresenius Kabi
  38. 8.7.1 Fresenius Kabi Company Information
  39. 8.7.2 Fresenius Kabi Business Overview
  40. 8.7.3 Fresenius Kabi Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Fresenius Kabi Direct Thrombin Inhibitors (DTIs) Product Portfolio
  42. 8.7.5 Fresenius Kabi Recent Developments
  43. 8.8 GlaxoSmithKline
  44. 8.8.1 GlaxoSmithKline Company Information
  45. 8.8.2 GlaxoSmithKline Business Overview
  46. 8.8.3 GlaxoSmithKline Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GlaxoSmithKline Direct Thrombin Inhibitors (DTIs) Product Portfolio
  48. 8.8.5 GlaxoSmithKline Recent Developments
  49. 8.9 Hikma
  50. 8.9.1 Hikma Company Information
  51. 8.9.2 Hikma Business Overview
  52. 8.9.3 Hikma Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Hikma Direct Thrombin Inhibitors (DTIs) Product Portfolio
  54. 8.9.5 Hikma Recent Developments
  55. 8.10 Mitsubishi Tanabe Pharma
  56. 8.10.1 Mitsubishi Tanabe Pharma Company Information
  57. 8.10.2 Mitsubishi Tanabe Pharma Business Overview
  58. 8.10.3 Mitsubishi Tanabe Pharma Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Mitsubishi Tanabe Pharma Direct Thrombin Inhibitors (DTIs) Product Portfolio
  60. 8.10.5 Mitsubishi Tanabe Pharma Recent Developments
  61. 8.11 MSN
  62. 8.11.1 MSN Company Information
  63. 8.11.2 MSN Business Overview
  64. 8.11.3 MSN Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 MSN Direct Thrombin Inhibitors (DTIs) Product Portfolio
  66. 8.11.5 MSN Recent Developments
  67. 8.12 Pfizer
  68. 8.12.1 Pfizer Company Information
  69. 8.12.2 Pfizer Business Overview
  70. 8.12.3 Pfizer Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Pfizer Direct Thrombin Inhibitors (DTIs) Product Portfolio
  72. 8.12.5 Pfizer Recent Developments
  73. 8.13 Sandoz
  74. 8.13.1 Sandoz Company Information
  75. 8.13.2 Sandoz Business Overview
  76. 8.13.3 Sandoz Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Sandoz Direct Thrombin Inhibitors (DTIs) Product Portfolio
  78. 8.13.5 Sandoz Recent Developments
  79. 8.14 Teva Pharmaceutical
  80. 8.14.1 Teva Pharmaceutical Company Information
  81. 8.14.2 Teva Pharmaceutical Business Overview
  82. 8.14.3 Teva Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Teva Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio
  84. 8.14.5 Teva Pharmaceutical Recent Developments
  85. 8.15 The Medicines Company
  86. 8.15.1 The Medicines Company Company Information
  87. 8.15.2 The Medicines Company Business Overview
  88. 8.15.3 The Medicines Company Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 The Medicines Company Direct Thrombin Inhibitors (DTIs) Product Portfolio
  90. 8.15.5 The Medicines Company Recent Developments
  91. 8.16 Beijing Baiao Pharmaceutical
  92. 8.16.1 Beijing Baiao Pharmaceutical Company Information
  93. 8.16.2 Beijing Baiao Pharmaceutical Business Overview
  94. 8.16.3 Beijing Baiao Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Beijing Baiao Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio
  96. 8.16.5 Beijing Baiao Pharmaceutical Recent Developments
  97. 8.17 BrightGene
  98. 8.17.1 BrightGene Company Information
  99. 8.17.2 BrightGene Business Overview
  100. 8.17.3 BrightGene Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 BrightGene Direct Thrombin Inhibitors (DTIs) Product Portfolio
  102. 8.17.5 BrightGene Recent Developments
  103. 8.18 Chengdu Brilliant Pharmaceutical
  104. 8.18.1 Chengdu Brilliant Pharmaceutical Company Information
  105. 8.18.2 Chengdu Brilliant Pharmaceutical Business Overview
  106. 8.18.3 Chengdu Brilliant Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Chengdu Brilliant Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio
  108. 8.18.5 Chengdu Brilliant Pharmaceutical Recent Developments
  109. 8.19 Hainan Poly Pharm
  110. 8.19.1 Hainan Poly Pharm Company Information
  111. 8.19.2 Hainan Poly Pharm Business Overview
  112. 8.19.3 Hainan Poly Pharm Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Hainan Poly Pharm Direct Thrombin Inhibitors (DTIs) Product Portfolio
  114. 8.19.5 Hainan Poly Pharm Recent Developments
  115. 8.20 Hainan Shuangcheng Pharmaceuticals
  116. 8.20.1 Hainan Shuangcheng Pharmaceuticals Company Information
  117. 8.20.2 Hainan Shuangcheng Pharmaceuticals Business Overview
  118. 8.20.3 Hainan Shuangcheng Pharmaceuticals Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Hainan Shuangcheng Pharmaceuticals Direct Thrombin Inhibitors (DTIs) Product Portfolio
  120. 8.20.5 Hainan Shuangcheng Pharmaceuticals Recent Developments
  121. 8.21 Hansoh Pharma
  122. 8.21.1 Hansoh Pharma Company Information
  123. 8.21.2 Hansoh Pharma Business Overview
  124. 8.21.3 Hansoh Pharma Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Hansoh Pharma Direct Thrombin Inhibitors (DTIs) Product Portfolio
  126. 8.21.5 Hansoh Pharma Recent Developments
  127. 8.22 Lunan Pharmaceutical
  128. 8.22.1 Lunan Pharmaceutical Company Information
  129. 8.22.2 Lunan Pharmaceutical Business Overview
  130. 8.22.3 Lunan Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Lunan Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio
  132. 8.22.5 Lunan Pharmaceutical Recent Developments
  133. 8.23 Qilu Pharmaceutical
  134. 8.23.1 Qilu Pharmaceutical Company Information
  135. 8.23.2 Qilu Pharmaceutical Business Overview
  136. 8.23.3 Qilu Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Qilu Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio
  138. 8.23.5 Qilu Pharmaceutical Recent Developments
  139. 8.24 CSPC Ouyi Pharmaceutical
  140. 8.24.1 CSPC Ouyi Pharmaceutical Company Information
  141. 8.24.2 CSPC Ouyi Pharmaceutical Business Overview
  142. 8.24.3 CSPC Ouyi Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  143. 8.24.4 CSPC Ouyi Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio
  144. 8.24.5 CSPC Ouyi Pharmaceutical Recent Developments
  145. 8.25 Yangtze River Pharmaceutical
  146. 8.25.1 Yangtze River Pharmaceutical Company Information
  147. 8.25.2 Yangtze River Pharmaceutical Business Overview
  148. 8.25.3 Yangtze River Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Yangtze River Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio
  150. 8.25.5 Yangtze River Pharmaceutical Recent Developments
  151. 8.26 Chia Tai Tianqing Pharmaceutical
  152. 8.26.1 Chia Tai Tianqing Pharmaceutical Company Information
  153. 8.26.2 Chia Tai Tianqing Pharmaceutical Business Overview
  154. 8.26.3 Chia Tai Tianqing Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales, Price, Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Chia Tai Tianqing Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio
  156. 8.26.5 Chia Tai Tianqing Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Direct Thrombin Inhibitors (DTIs) Value Chain Analysis
  2. 9.1.1 Direct Thrombin Inhibitors (DTIs) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Direct Thrombin Inhibitors (DTIs) Production Mode & Process
  6. 9.2 Direct Thrombin Inhibitors (DTIs) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Direct Thrombin Inhibitors (DTIs) Distributors
  9. 9.2.3 Direct Thrombin Inhibitors (DTIs) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst